Amit Vasavada - 07 Feb 2022 Form 4/A - Amendment Insider Report for MARRONE BIO INNOVATIONS INC

Role: SVP & CTO
Signature: /s/ Linda V. Moore, as attorney in fact
Issuer symbol: N/A
Transactions as of: 07 Feb 2022
Net transactions value: +$50,240
Form type: 4/A - Amendment
Filing time: 18 Mar 2022, 17:41:47 UTC
Date Of Original Report: 09 Feb 2022
Previous filing: 27 May 2021
Next filing: 15 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBII	Common Stock	Award	$50,240	+79,481	+202%	$0.6321	118,830	07 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBII	Stock Option (Right to Buy)	Award	$0	+185,455		$0.000000	185,455	07 Feb 2022	Common Stock	185,455	$0.6321	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 7, the reporting person was granted 79,481 restricted stock units, which represent a contingent right to receive one share of Issuer's common stock. The restricted stock units vest pursuant to the Vesting Schedule (as defined in footnote (2)) and are delivered to the reporting person upon vesting.
F2	The awards vest in equal monthly installments over three years, subject to the recipient's continued employment by the Issuer through the applicable vesting date, provided that, in lieu of the terms of any change in control agreement in place between the Issuer and the reporting person, in the event that the reporting person resigns for Good Reason (as defined in the recipient's change in control agreement) or is terminated without Cause (as defined in recipient's change in control agreement) within twelve months of a Change in Control (as defined in recipient's change in control agreement), 50% of the unvested portion of the awards will become immediately vested (the "Vesting Schedule").
F3	The original Form 4, filed on February 9, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misstated the expiration date as February 6, 2025.